BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Drug Development

  CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

  September 27, 2024

   · 

  14 min read
• Drug Development

  Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

  September 27, 2024

   · 

  12 min read
• FDA

  GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

  September 27, 2024

   · 

  12 min read
• Press Releases

  Establishment Labs Receives U.S. FDA Approval for Motiva Implants

  September 27, 2024

   · 

  8 min read
• Press Releases

  FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

  September 27, 2024

   · 

  3 min read
• Press Releases

  BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

  September 27, 2024

   · 

  18 min read
• Press Releases

  Cue Biopharma Announces Pricing of $12.0 Million Public Offering

  September 27, 2024

   · 

  5 min read
• Press Releases

  U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

  September 27, 2024

   · 

  16 min read
• Press Releases

  Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

  September 27, 2024

   · 

  9 min read
• Press Releases

  Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities

  September 27, 2024

   · 

  3 min read